First, analysis of other co-mutations and sub-analysis of specific co-mutations was not possible in our study because of the rarity of TERT promoter mutations, with its prevalence reported to be between 4.2% and 25% in well-differentiated thyroid cancer. This evidence concerns the gene TERT and thyroid gland carcinoma.